JP2022535410A5 - - Google Patents
Info
- Publication number
- JP2022535410A5 JP2022535410A5 JP2021571870A JP2021571870A JP2022535410A5 JP 2022535410 A5 JP2022535410 A5 JP 2022535410A5 JP 2021571870 A JP2021571870 A JP 2021571870A JP 2021571870 A JP2021571870 A JP 2021571870A JP 2022535410 A5 JP2022535410 A5 JP 2022535410A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- taci
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856998P | 2019-06-04 | 2019-06-04 | |
| US62/856,998 | 2019-06-04 | ||
| US201962907930P | 2019-09-30 | 2019-09-30 | |
| US62/907,930 | 2019-09-30 | ||
| US202063012735P | 2020-04-20 | 2020-04-20 | |
| US63/012,735 | 2020-04-20 | ||
| PCT/US2020/036108 WO2020247618A1 (en) | 2019-06-04 | 2020-06-04 | Antibodies and chimeric antigen receptors that target taci |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535410A JP2022535410A (ja) | 2022-08-08 |
| JP2022535410A5 true JP2022535410A5 (cg-RX-API-DMAC7.html) | 2023-06-13 |
| JP7584453B2 JP7584453B2 (ja) | 2024-11-15 |
Family
ID=73652958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571870A Active JP7584453B2 (ja) | 2019-06-04 | 2020-06-04 | Taciを標的とする抗体及びキメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12595303B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3980454A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7584453B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114206919B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020287626A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3139057A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247618A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020247618A1 (en) | 2019-06-04 | 2020-12-10 | The General Hospital Corporation | Antibodies and chimeric antigen receptors that target taci |
| CN117425670A (zh) * | 2021-05-19 | 2024-01-19 | 细胞编辑有限责任公司 | 双特异性嵌合抗原受体和表达此类双特异性嵌合抗原受体的基因工程化免疫细胞 |
| US20250195651A1 (en) * | 2022-03-15 | 2025-06-19 | Celledit Llc | Use of antigen presenting cells to enhance car-t cell therapy |
| WO2024056009A1 (zh) * | 2022-09-14 | 2024-03-21 | 荣昌生物制药(烟台)股份有限公司 | 一种taci抗体及其用途 |
| US20260015430A1 (en) * | 2022-11-08 | 2026-01-15 | Agency For Science, Technology And Research | Antigen binding protein specific for transmembrane activator and caml interactor (taci) |
| CN117288933A (zh) * | 2023-09-21 | 2023-12-26 | 桂林医学院附属医院 | 检测car-t细胞杀伤力的方法 |
| CN121975012B (zh) * | 2026-04-07 | 2026-06-26 | 国典(北京)医药科技有限公司 | 一种靶向taci的纳米抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| BR0313033A (pt) | 2002-07-25 | 2007-07-10 | Genentech Inc | anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica |
| WO2004074511A1 (en) | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
| AU2008219972A1 (en) | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient |
| EP3243831A1 (en) * | 2014-02-27 | 2017-11-15 | Ucl Business Plc | Variants of the proliferation-inducing ligand (april) |
| WO2017040324A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| PL3896091T3 (pl) | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| CA3042613A1 (en) * | 2016-11-11 | 2018-05-17 | Autolus Limited | Chimeric antigen receptor |
| CN108490174B (zh) | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
| WO2020247618A1 (en) | 2019-06-04 | 2020-12-10 | The General Hospital Corporation | Antibodies and chimeric antigen receptors that target taci |
-
2020
- 2020-06-04 WO PCT/US2020/036108 patent/WO2020247618A1/en not_active Ceased
- 2020-06-04 US US17/616,274 patent/US12595303B2/en active Active
- 2020-06-04 CA CA3139057A patent/CA3139057A1/en active Pending
- 2020-06-04 CN CN202080054113.3A patent/CN114206919B/zh active Active
- 2020-06-04 AU AU2020287626A patent/AU2020287626A1/en active Pending
- 2020-06-04 EP EP20818549.6A patent/EP3980454A4/en active Pending
- 2020-06-04 JP JP2021571870A patent/JP7584453B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI883026B (zh) | 抗dll3嵌合抗原受體及其用途 | |
| JP7809680B2 (ja) | 癌処置のための多重特異性結合タンパク質 | |
| JP2022512684A5 (cg-RX-API-DMAC7.html) | ||
| JP2022504802A5 (cg-RX-API-DMAC7.html) | ||
| JP2022542543A5 (cg-RX-API-DMAC7.html) | ||
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| JP2017527275A5 (cg-RX-API-DMAC7.html) | ||
| US20240209106A1 (en) | Anti-cd137 antibodies and methods of use | |
| US20240190983A1 (en) | Novel TNFR2 Binding Molecules | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| JP2023511898A5 (cg-RX-API-DMAC7.html) | ||
| US20240400705A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| JP2025528835A5 (cg-RX-API-DMAC7.html) | ||
| WO2024193669A1 (zh) | 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用 | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JP2024514101A5 (cg-RX-API-DMAC7.html) | ||
| CN117164719A (zh) | 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用 | |
| WO2024094151A1 (en) | Multi-specific antibody and medical use thereof | |
| RU2023128561A (ru) | Gucy2c-связывающий полипептид и его применение | |
| JP2025539145A (ja) | 抗cd137抗体及びその使用方法 | |
| EP4419109A1 (en) | Uses of gamma delta t cell activating antibodies | |
| JP2025087939A (ja) | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用 | |
| HK40065826A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| Zhu et al. | Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer | |
| HK40108650A (en) | Single-domain 4-1bb antibodies |